Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.33 +1.91%

+$0.03 today

Market cap
$139.83M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.09M

Average 0.07M

IPHA EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Innate Pharma S.A.NASDAQ: IPHA

EBITDA · Q4 FY2025 · quarter ended Dec 2025

EBITDA remains negative

Q4 FY2025 EBITDA was -€30.71M, compared with -€21.35M a year earlier.

Context

  • EBITDA amounted to 1566.1% of revenue in FY2025, up 1194.4 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of €1.74M (+104.0%) for the fiscal year ending Dec 2026, a step up from the +7.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-€30.71M— QoQ
Last fiscal yearDec 2025
-€43.65M+7.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.8%——
1 year+7.0%+104.0%+97.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

EUR · from the income statement

Latest · FY2025
(43.65M) EUR
Year-over-year change
+7.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How IPHA compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.0% is the 5th highest of 9, against a peer median of +0.6%.
  • EBITDA amounts to 1566.1% of revenue for IPHA, versus a peer median of 2246.5%.
IPHA Competitors
EBITDA for IPHA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGENCompugen Ltd.LTM Mar 2026$34.88M USD+463.6%—48.0%
NVCTNuvectis Pharma, Inc.LTM Mar 2026-$28.06M USD-39.2%——
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$33.38M USD+31.6%—1053.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$37.68M USD+23.9%——
IPHAInnate Pharma S.A.FY2025-€43.65M EUR+7.0%—1566.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026-$43.73M USD+9.5%—8329.5%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$61.36M USD-27.4%—3439.7%
MOLNMolecular Partners AGLTM Mar 2026-CHF 63.08M CHF-8.3%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.28M USD-67.4%——
Peer median (excluding IPHA) —+0.6%—2246.5%

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.11M57.67M51.9M12.62M2.79M
Cost of Revenue47M51.66M56.02M51.98M0
Gross Profit(22.3M)6.01M5.62M12.62M2.79M
Gross Margin-184.1%10.4%10.8%100.0%100.0%
Research & Development47M51.66M56.02M51.98M43.62M
Selling, General & Admin25.52M14.47M11.75M11.93M11M
Operating Expenses25.52M63.44M18.29M64.2M56.21M
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
EBITDA(43.23M)(12.28M)(1.84M)(46.91M)(43.65M)
EBITDA Margin-356.9%-21.3%-3.5%-371.7%-1566.1%
Operating Income(47.83M)(57.43M)(12.67M)(51.58M)(53.43M)
Operating Margin-394.9%-99.6%-24.4%-408.6%-1916.9%
Interest Income327K546K3.18M2.44M1.32M
Interest Expense312K288K640K566K440K
Other Income / Expenses2.35M(547K)5.1M2.1M4.25M
Income Before Tax(45.48M)(57.97M)(7.57M)(49.47M)(49.18M)
Pre-Tax Margin-375.5%-100.5%-14.6%-392.0%-1764.5%
Income Tax Expense00000
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Net Margin-436.0%-100.7%-14.6%-392.0%-1764.5%
EPS (Basic)(0.57)(0.73)(0.09)(0.61)(0.53)
EPS (Diluted)(0.57)(0.73)(0.09)(0.61)(0.53)
Weighted Avg Shares79.54M79.59M84.11M81.05M89.42M
Weighted Avg Shares (Diluted)79.54M79.64M84.11M81.05M89.42M

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$1.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.